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ABSTRACT 
Objective: This study aimed to enhance the oral solubility and dissolution of poorly soluble lornoxicam by anti-solvent precipitation, and the 
manufacture of oral tablets by the phase transition method.  
Methods: The solvent was mixture of polyethylene glycol 400 and absolute ethanol. Three stabilizers Inutec SP1, Pluronic F127, Sucrose ester 
S1670 at two concentrations and two matrix formers Mannitol, and Avicel PH102 were used to obtain 12 formulae. The formulae were 
characterized regarding their infrared spectroscopy (IR), differential scanning calorimetry (DSC), particle size (PS) measurement, drug content and 
dissolution. Further characterizations were done for the optimum formula by scanning electron microscopy (SEM) and X-ray diffraction (XRD). Four 
tablet formulae were manufactured by phase transition method. The optimum tablets (T3) were evaluated through hardness, drug content, 
disintegration, dissolution, IR, and stability studies. Finally, (T3) was compared to conventional tablets in New Zealand rabbits using crossover 
design. 
Results: The dissolution rate for the prepared formulae was enhanced, from 3.44 to 5.96 folds. Statistical significance was obtained using one and 
two way ANOVA among formulae. The optimum tablet formula (T3) had hardness 5.637±1.57 kg, drug content 90.424±1.19%, disintegration time 
341.5±9.62 s and the drug dissolved 72.107±0.0025%. Stability, after one month storage of the selected tablets at (25 °c/60% relative humidity), 
was satisfactory. The absorption extent of lornoxicam from (T3) compared to the conventional tablets was higher. 
Conclusion: Taken together, the obtained results confirmed successfully the potential of the promising formula (T3), over the conventional tablets 
of lornoxicam. 
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INTRODUCTION 
Significant attention focused on nanomaterial based drug delivery 
has been propelled to the forefront by researchers. Owing to the 
fact that many emerging drug candidates have become more 
hydrophobic and less water soluble, designing an adequate oral 
dosage form as the oral route is the most common route for drug 
administration due to its convenience has become challenging and 
researchers frequently have to consider more complex drug delivery 
platforms [1]. The potent Lornoxicam is used for anti-inflammatory and 
analgesic purposes in osteoarthritis and rheumatoid arthritis [2, 3]. 
Lornoxicam is slightly acidic with a pKa (acid dissociation constant) 
of 4.7 and hence has limited dissolution in an acidic environment [4]. 
It is slightly lipophilic with an apparent partition coefficient of 1.8 
(n-octanol/buffer pH 7.4) [5]. It exhibits low solubility and high 
permeability (class II) [6]. This can make its absorption and 
dissolution rate limited and thus delay the onset of action. An 
enhancement in the solubility and the dissolution rate can firstly, 
improve its oral bioavailability, secondly, improve its therapeutic 
efficiency and the patient compliance [7]. Anti-solvent precipitation 
method is an effective bottom-up technique to prepare nanosized 
drug particles [8]. The aim of the work is to speed up the dissolution 
of lornoxicam in the gastric pH 1.2 by its formulation as 
nanoparticles utilizing anti-solvent precipitation technique, with the 
aid of different stabilizers, Inutec SP1, Pluronic F127 or Sucrose 
ester S1670 at different concentrations followed by lyophilization of 
the processed nanoparticles using either Mannitol or Avicel pH 102 
as matrix formers. The lornoxicam formula which showed the 
optimum dissolution profile (F3) was selected for further 
characterization and formulation by phase transition of sugar 
alcohols into oral film coated tablets. Mizumoto et al., reported that 
oral disintegrating tablets could be manufactured using a 
combination of saccharides with the low and high moldability [9]. 
The tablet hardness was increased by the crystal change from an 
amorphous to a crystal state by the conditioning process. This 
method provides sufficient hardness and low disintegration time 
for tablets. Moreover, stability study was evaluated for a month, 
and in vivo study was also performed in rabbits to estimate the 
pharmacokinetic parameters for the optimized tablet formulation 
(T3) and to calculate the relative bioavailability in comparison to 
oral conventional tablets which was 2.04 folds higher.  
MATERIALS AND METHODS 
Materials 
Lornoxicam (C13H10Cl N3O4 S2, MW: 371.8192 g/mol) was a gift 
from Global Napi drug company Ltd (6th October city, Egypt). 
Polyethylene glycol 400, LOBA Chemie, (India). Hydrochloric acid 
from Scharlau, (Spain). Absolute ethanol 99.9% of International 
Company for Sup. and Med. industries Alamia, (Egypt). Phosphate 
buffer PH 6.8 components (Sodium Chloride, Disodium hydrogen 
phosphate, Potassium dihydrogen phosphate) from Adwic, El-Nasr 
Pharmaceutical Chemicals Co., (Egypt). Avicel pH 102 FMC Co., 
(Penselvania, USA). Pluronic F127 from Sigma-Aldrich, Inc., 
(Germany). Inutec SP1 from Beneo, (Germany). Sucrose ester S1670 
from Ryoto™ (Japan). The water was distilled de-ionized water. 
Mannitol and Lactose anhydrous high melting point sugars from 
Adwic, El-Nasr Pharmaceutical Chemicals CO. (Egypt). Xylitol, low 
melting point sugar alcohol, Xylisorb® and Lycoat® RS 720, medium 
viscosity grade from Roquette Pharma (France). Pruv® (Sodium 
stearyl fumarate), lubricant, from JRS Pharma (USA). Vivapharm® 
HPMC E5-Hypromellose from JRS Pharma (USA). Sodium nitrite 
from Adwic, El-Nasr Pharmaceutical Chemicals CO. (Egypt). 
Acetonitrile 80%, 0.1% Formic acid, tertiary butyl methyl ether 
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(HPLC grade) were provided by Merck (Darmstadt, Germany). 
Lornoxicam® 8 mg (Global Pharmaceutical Industries, Egypt) was 
used as a reference tablet in in vivo studies. 
Methods 
Preparation of nanosized lornoxicam through anti-solvent 
precipitation method 
Lornoxicam nanoparticles were produced through anti-solvent 
precipitation followed by freeze-drying. A mixture of absolute 
ethanol and the co-solvent polyethylene glycol 400 in a ratio of 2:3 
respectively was used as the solvent for lornoxicam [10]. Dissolution 
of lornoxicam was affected by ultrasonication until completely 
dissolved using (ultrasonicator LC 60 H, Elma, Germany). Precooled 
freshly double distilled water was used as anti-solvent containing 
one of three stabilizers which are Pluronic F127 with concentrations 
(0.02% w/v, and 0.08% w/v) [11], Inutec SP1 with concentrations 
(0.005% w/v, and 0.009% w/v) [12] and Sucrose ester S1670 with 
concentrations (0.001% w/v, and 0.002% w/v) [13]. Lornoxicam 
solution was completely poured into the anti-solvent (containing a 
certain concentration of surfactant) in a ratio 1:5 with vigorous 
magnetic stirring using (Magnetic stirrer, 1200 Hot plate and stirrer, 
Jenway, UK). Lornoxicam nanoparticles immediately precipitated 
from the solution upon mixing. After stirring for a predetermined 
time the nanoparticle suspension was sonicated using the probe 
sonicator (Sonics vibra cell, 20 KHZ±50 HZ, USA) under controlled 
temperature using an ice-bath with continuous sonication for 5 min. 
The obtained nanoparticles were concentrated by centrifugation at 
13500 rotations per minute (rpm) for 15 min at 4 °C using cooling 
centrifuge (Sigma, 3-30 K, D-37520, Germany). After the 
centrifugation, the supernatant was replaced with fresh double 
distilled water for washing. The collected nanoparticles were 
redispersed in deionized water containing cryoprotectants 
(mannitol 3% w/v or avicel at ratio 1:1w/w), prefrozen at–40 °C for 
2 h, and subsequently lyophilized at –40 °C for 48 h to obtain 
lornoxicam nanoparticles powder [14]. 
Characterization of different lornoxicam nano formulations 
DSC 
DSC patterns were done for the raw drug, excipients, and the 
formulae using the DSC instrument (Shimadzu, Model TA ─ 50, ESI, 
Kyoto, Japan). Temperature range was 20 ─ 300 °C and the heating 
rate were 10 °C/min. [15]. 
IR  
The infrared spectra were done for the raw drug, excipients, and the 
formulae which were recorded over a wave number range of 4000 
cm-¹ to 400 cm-¹ (IR Affinity-1, Shimadzu, Kyoto, Japan) [16]. 
Drug content determination 
Lornoxicam content of different nanoparticle formulae was 
determined by dissolving 10 mg of each formula in 100 ml 
phosphate buffer pH 6.8 using sonicator, then the absorbance was 
measured spectrophotometrically at 376 nm (UV-Vis 
spectrophotometer, Shimadzu UV-1650 PC double beam–Japan) 
using phosphate buffer pH 6.8 as the blank and the percentage drug 
content was calculated. Each experiment was carried out in 
triplicate, and the mean drug content in each formulation was 
determined [17]. 
In vitro dissolution studies  
The dissolution experiment of raw lornoxicam (8 mg) and 
lornoxicam nanoparticle formulae (equivalent to 8 mg of 
lornoxicam) were carried out using the USP dissolution tester 
apparatus (II) (Dis 6000, Pharmatron, Switzerland). The stirring 
speed was 100 (rpm), the temperature was 37.0±0.5 °C and 900 ml 
of 0.1 N HCl pH 1.2 was used as the dissolution medium. Aliquots of 
5 ml were collected after 5, 10, 15, 20, 25, 30, 40, 50 and 60 min and 
immediately supplemented with the same volume of fresh medium. 
Finally, the concentrations of the collected aliquots were determined 
spectrophotometrically against a blank at 372 nm in acidic medium. 
The experiment was done in triplicate and the mean values of 
cumulative percentage drug dissolved were plotted versus time [18]. 
PS analysis 
The size of different lornoxicam nano formulations and poly dispersity 
index (PDI) were measured by dynamic laser light scattering (Nano–
Zetasizer, Malvern ZS, Zen 3600, England). Before analysis 2 mg of 
the drug nanoparticles of different formulae was dispersed in 15 ml 
of deionized water and sonicated for 2 min. The measurements were 
done in triplicate [19].  
SEM 
The external morphology of raw lornoxicam and the lornoxicam 
nanoparticles formula of choice were examined through scanning 
electron microscopy (Quanta 250, FEG, Holland). Particles of the 
representative samples were fixed on SEM stub using double-sided 
adhesive tape. Before observation, the formulae were coated with a 
thin layer of gold [20]. 
XRD 
The solid state of raw lornoxicam and the lornoxicam nanoparticles 
formula of choice were examined using an x-ray diffractometer 
(Philips, X’Pert Pro, Netherlands) with secondary Monochromator. 
The current and voltage using Cu-radiation were generated at 35 mA 
and 45 kV, respectively. The angular range was scanned from 0 ° to 
60 ° of 2θ, with a scanning speed 0.02 °/s [21]. 
Statistical analysis 
Statistical analysis of the results was performed using one way 
ANOVA followed by Post hoc analysis using Dunnett's test in terms 
of particle size, percentage drug content, while using two way 
ANOVA followed by Post hoc analysis using Dunnett's test in terms 
of percentage drug dissolved at (5, 20, and 60 min) of nano formulae 
and raw lornoxicam using SPSS software version 24 (Statistical 
Package for the Social Science; SPSS Inc., Chicago, IL, USA). The level 
of significance was set at 0.05, and (*p<0.05) was considered to be 
statistically significant. 
Preparation of film coated tablets by phase transition of sugar 
alcohols 
The optimum nanoparticle formula (F3) was prepared in the form of 
rapid release tablet using the phase transition method, a 
combination of two types of sugar alcohols was used, either 
mannitol as the high sugar alcohol (166-168 °C) and xylitol as low 
melting point sugar alcohol (93-95 °C) or lactose as higher melting 
point sugar alcohol (201.6-203.3 °C) and xylitol such that the ratio 
between the low and the high melting point sugar alcohols was 1:19. 
The sugar alcohols were mixed in a bottle for 3 min, with the 
concentration of the low melting point sugar alcohol in the mixture 
being set at 5%. The mixture was compressed by a single punch 
machine (Karishma Pharma Machines, India) under the following 
conditions: weight, 150 mg; compression pressure, 500 kgf; punch, 7 
mm in diameter. The obtained tablets were coated by HPMC E-5 for 
T1 and T3, while T2 and T4 were coated using Lycoat RS 720; the 
coating process was manual by spraying, then tablets were placed in 
a drying oven to heat at 97 °C for 30 min. Finally, tablets were 
allowed to cool at room temperature [22-24]. 
Characterization of tablets 
Uniformity of weight 
The test was carried out according to the British Pharmacopoeia 
(BP) [25]. Twenty tablets from each formula, were individually 
weighed and the mean of tablet weights was calculated. Results are 
presented as mean value±standard deviation (SD). 
Tablet friability 
Twenty tablets, from each formula, were accurately weighed and 
placed in the drum of friabilator (Thermonik type, Campbell 
electronics, India). The tablets were rotated at 25 (rpm) for a period 
of 4 min and then removed, dedusted and accurately re-weighed. 
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The percentage loss in weight was calculated and taken as a measure 
of friability [25]. 
Tablet hardness 
According to the British Pharmacopoeia, ten tablets from each 
formula, were tested using hardness tester (Thermonik type, 
Campbell electronics, India). The mean hardness was calculated in 
kg±SD [25]. 
Drug content uniformity 
Randomly selected ten tablets from each formula were assayed for 
drug content uniformity. Lornoxicam was assayed by dissolving one 
tablet in phosphate buffer pH 6.8 [26] with the aid of an ultra 
sonicator (Elma Sonicator, Germany) for one hour to ensure 
complete dissolution. Lornoxicam was assayed 
spectrophotometerically at λmax 372 nm, using UV spectroscopy 
(Shimadzu-1650 PC double beam, Japan). The percentage of 
lornoxicam was calculated as the mean of three recordings±SD. 
In vitro disintegration time 
Disintegration times of the prepared tablets were determined with 
six tablets in 900 ml of simulated gastric fluid Kept at 37±0.5 °c 
using (Thermonik type, Campbell electronics, India). According to 
European Pharmacopoeia (2009) specifications [27]. The 
disintegration time was defined as the time necessary for the tablet 
to completely disintegrate until no solid residue remains or only a 
trace amount of soft residue remains on the screen. A digital 
stopwatch was used to measure the disintegration time to the 
nearest second. All results are presented as mean value±SD. 
In vitro dissolution studies 
The dissolution profiles of lornoxicam in tablets compared with the 
raw drug were determined in a dissolution tester (Hanson Vision 
Elite 8, USA) following the USP Paddle Method. All tests were 
conducted in 900 ml simulated gastric fluid without enzymes at pH 
1.2. The dissolution medium was maintained at a temperature of 
37±0.5 °c with a paddle rotation speed at 100 (rpm). The amount of 
drug used was equivalent to 8 mg. At specified time intervals (5, 10, 
15, 20, 25, 30, 40, 50, and 60 min), 5 ml aliquots were withdrawn 
and replaced with equal volume of fresh medium to maintain the 
sink condition. Samples were assayed for drug content 
spectrophotometerically at 372 nm [28]. Cumulative amount of drug 
dissolved in the preparations was calculated according to the 
calibration equation. Dissolution studies were performed in 
triplicates (n=3). 
IR 
Samples of (2-3 mg) was ground with dry potassium bromide 
powder, and compressed into discs. The IR spectra were recorded 
(IR Affinity-1, Shimadzu, Kyoto, Japan) for tablet formulae, and the 
excipients. The test was done in triplicates [16]. 
Statistical analysis 
The experimental results were analyzed using SPSS software version 
24. One way ANOVA was used to show the significance of the 
difference between formulae at a level of 0.05 in terms of hardness, 
disintegration time and dissolution. Post hoc analysis was 
performed using the Scheffe test. 
Stability study 
A stability test was done for the optimum tablet formula (T3) 
prepared by direct compression using the phase transition method. 
The storage conditions were set at 25 °c/60% relative humidity 
(RH) for one month in waterproof containers in desiccator 
containing saturated solution of sodium nitrite. Evaluation tests 
were done for the fresh and the stored tablets; after a week, two 
weeks and four weeks for their lornoxicam content, tensile strength, 
disintegration time and in vitro release [24]. 
In vivo studies 
The design of this study was a comparative, randomized, single dose, 
two-way crossover open-label study performed in two phases using 
the two formulations: Lornoxicam® 8 mg film coated tablets as a 
reference product and the optimized formula tablets (T3) (8 mg). 
Twelve healthy male New Zealand rabbits (2.0─2.5 kg) participated 
in the study, and were randomly assigned into two groups of equal 
size. The study procedure performed was approved by the Ethics 
Committee of Faculty of Pharmacy, Cairo University (PI 1947), 
Egypt. The animals were kept in individual cages under well-defined 
and standardized conditions (humidity, and temperature controlled 
room), fed with standard food and water access, and allowed to fast 
overnight for 12 h [29]. On the study day, each rabbit in the first 
group received equivalent amount to (8 mg) of conventional tablet 
(Treatment A). The tablets were placed gently into the mouth of the 
rabbits and swallowed with the aid of the water. Rabbits of the 
second group received equal doses of lornoxicam through oral 
administration of optimum formula (T3) (Treatment B). From the 
start of the study time, the rabbits remained at the study site under 
controlled dietary and liquid intake until the end of the study day. 
The washout time was one week. Venous blood samples (250 µl) 
were collected in heparinized glass tubes to prevent blood clotting at 
the following scheduled time intervals: 0 (predose), 15, 30, 45, 60, 
90 min, 2, 3, 4, 6, 8, 12, 15, and 24 h after administration of both 
treatments. Plasma was immediately separated from the blood cells 
via centrifugation (3000 rpm) for 10 min (Centurion Scientific Ltd., 
Chichester, UK), kept in glass tubes and then deep frozen at ─ 25 °C 
till assayed. 
Instrumentation  
The analysis was performed using a Shimadzu Prominence 
(Shimadzu, Japan) series LC system equipped with degasser (DGU-
20A3) and solvent delivery unit (LC-20AD) with an auto-sampler 
(SIL-20A). The system was used to inject 25 µl aliquots of the 
processed samples on a C18, 100A (50×4.6 mm) (Phenomenex, 
USA), 5 µm particle size. A sensitive and validated LC-MS/MS was 
adopted for the separation and quantitation of lornoxicam using 
Torsemide as an internal standard (IS) [30]. The mobile phase 
consisted of acetonitrile and 0.1% formic acid in water (80:20 v/v) 
was pumped at 1 ml/min. MS/MS detection in positive ion mode 
using AB Sciex (Foster City, CA, USA) API-3200 mass spectrometer 
was used for quantitation. The analytical data were processed by 
Analyst Software version 1.6 (Applied Biosystems Inc., Foster city, 
CA) [31]. 
Standard solution and sample preparation 
To prepare the standard calibration samples, aliquots of 1 ml rabbit 
plasma were spiked with lornoxicam stock solution (50 ng/ml) and 
an aliquot of 100 µl of Torsemide solution the internal standard (IS) 
to produce calibration standards at the following concentrations: 1, 
3, 12.5, 100, 300, 625, 1000 ng/ml. For sample preparation, 1 ml of 
rabbit plasma and 100 µl of Torsemide solution (IS) was vortexed in 
10 ml glass tubes for 1 min. Five milliliters of tertiary butyl methyl 
ether were added vortexed for another 1 min then centrifuged at 
3000 (rpm) for 10 min. The organic layer (3 ml) was transferred to 
clean glass tube and evaporated to dryness using centrifugal vacuum 
concentrator at 45 °C. The dry residue was reconstituted in 200 µl 
mobile phase and an aliquot of 20 µl of this solution was loaded into 
LC-MS/MS. 
Pharmacokinetic parameters and statistical calculations 
Peak concentrations (Cmax) and peak times (Tmax) were derived directly 
from the experimental points. The other pharmacokinetic parameters; 
(AUC0-24, AUC0-∞, Kel and t½e) were computed by non-compartmental 
analysis using Kinetica Software (version 4.4.1). The pharmacokinetic 
parameters of the two tested formulations (test and reference) were 
compared by using non-parameteric for independent samples (Mann-
Whitney’s test) using the SPSS software version 24. The significance of 
the difference was determined at (*p<0.05). 
RESULTS 
Preparation of nanosized lornoxicam through anti-solvent 
precipitation method 
Lornoxicam nanoparticles were prepared by the anti-solvent 
precipitation method. The drug solution was introduced to generate 
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high supersaturation, results in a high nucleation rate and produces a 
large number of nuclei, which reduced the solute mass for subsequent 
growth. The growth of nucleating crystals could be arrested by using a 
stabilizer through a steric or electrostatic mechanism [32]. For 
hydrophobic drugs like lornoxicam, water is most commonly used as 
anti-solvent. In terms of the solvent, blend of absolute ethanol and 
polyethylene glycol 400 in a ratio 2:3 screened by trial and error was 
used. The solubilization power was correlated with the co-solvent 
polarity; the greater the difference in polarity between the two 
solvents the greater the power of solubilization [10]. The stabilizer 
needs to have a good affinity for the drug particles, possesses a fast 
diffusion rate and effective adsorption onto the drug particle surface. 
So, the choice of appropriate solvent–stabilizer pair is empirical. The 
physical state of the formed particles was significantly influenced by 
many parameters as stirring rate; higher stirring rate favored the 
formation of smaller and more uniform drug particles, also the drug 
concentration and the solvent volume ratio [33]. The preparation 
temperature; a lower temperature can inhibit the particle growth, 
therefore the particles with small size were formed as a result of the 
high nucleation rate and low growth rate at low temperature [34]. 
After several trials and errors, the parameters of the method were, 
three stabilizers Inutec SP1, Pluronic F127, Sucrose ester S1670, each 
in two different ratios above and below their critical micelle 
concentrations of 0.009% w/v, 0.1% w/v, and 0.0014% w/v 
respectively [11-13], the temperature of anti-solvent below 3 °C, the 
stirring rate was 1500 (rpm), the ratio between the solvent and anti-
solvent was 1:5, the composition of the different formulae has 
complied in table 1. 
  
Table 1: Composition of different lornoxicam nano formulae 








Avicel pH 102  
(mg) 
F1 0.009   3  
F2 0.009    30 
F3 0.005   3  
F4 0.005    30 
F5  0.02  3  
F6  0.02   30 
F7  0.08  3  
F8  0.08   30 
F9   0.002 3  
F10   0.002  30 
F11   0.001 3  
F12   0.001  30 
*All the formulae contain 30 mg lornoxicam 
 
 
Fig. 1 (a): DSC thermograms of Lornoxicam (D), Mannitol, F1, F3, F5, F7, F9 and F11 
 
Characterization of nanoparticles 
DSC 
The compatibility of lornoxicam with the excipients was investigated 
using DSC since it is considered as a rapid method for evaluating the 
possible incompatibilities between drugs and excipients [35]. The 
DSC thermograms of raw lornoxicam, different formulae and the 
excipients are shown in fig. 1. Lornoxicam DSC thermogram 
exhibited a sharp exothermic peak at 233.8 °C corresponding to drug 
melting [36]. Avicel pH 102 showed a slightly exothermic effect 
above 300 °C that might be attributed to its melting or decomposition. 
Mannitol showed a sharp endothermic peak at 167 °C. It was evident 
that the exothermic peaks corresponding to both mannitol and 
avicel were preserved in the thermograms of all formulae. The 
lornoxicam exothermic peak was also evident in all of the 
thermograms of its formulae which might indicate compatibility. 
However, noticeable broadening in lornoxicam peak intensity was 
observed in some thermograms. This is probably attributed to the 
differences in geometry of the mixture samples reported by other 
authors [37]. Therefore, further compatibility investigation was 
performed applying infrared spectroscopy study. 
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Fig. 1(b): DSC thermograms of Lornoxicam (D), Avicel, F2, F4, F6, F8, F10 and F12 
 
IR 
The Fourier-transform infrared spectra (FTIR) of lornoxicam and 
the formulae were recorded and presented in fig. 2. It is clearly 
apparent that the IR spectrum of lornoxicam showed a characteristic 
peak at 3090 cm-1 corresponding to–NH stretching vibration. An 
intense absorption peak was found at 1642 cm-1 due to the 
stretching vibration of the C═O group in the primary amide. Other 
peaks were observed at 1597 cm-1 and at 1559 cm-1 showed the 
bending vibrations of the N–H group in secondary amide. Peaks 
obtained at 1157 cm-1, 1387 cm-1, 1336 cm-1 were due to stretching 
vibrations of O═S═O group. Other prominent peaks appeared at 
827.94 cm-1 corresponding to–CH aromatic ring bending and at 
766.8 cm-1 due to C–Cl bending vibration. It was clearly evident that 
the IR spectra of the different formulae showed no significant 
difference in peak intensities and wavelengths indicating the 
absence of chemical interaction between the drug and the excipients 
confirming the DSC results presented formerly. Therefore, the latter 
was considered in conjunction with DSC to reach a definite 
conclusion of drug excipient compatibility [38]. 
 
 
Fig. 2: FTIR spectra of Lornoxicam (D) and nanoparticles formulations 
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Drug content determination 
Table 2 showed the average percentage drug content of different 
formulae, which ranged from 25.759±0.119% to 100.508±0.034% 
and the standard deviation from triplicate determinations. It is 
evident that some formulae had high drug content and some were 
low; this is probably attributed to the number of nuclei formed at 
the solvent/anti-solvent interface and the influence of concentration 
on the viscosity [39]. The process parameters including the effect of 
temperature during mixing, rate of mixing, drug concentration, 
solvent/anti-solvent ratio, the choice of stabilizers used and their 
concentrations, cryoprotectants used, all played roles in degree of 
supersaturation and the nucleation rates which offer the potential to 
produce a large number of submicrometer particles in the final 
suspension, if the growth can be arrested by stabilizers [32]. The 
statistical analysis showed a significant difference between formulae 
by one way ANOVA followed by Dunnett’s test, and the highest 
content was in F3. 
 
Table 2: Percentage drug content of different formulae 













 *All values are (mean±SD (standard deviation), n= 3) 
 
In vitro dissolution studies 
In vitro dissolution studies for raw lornoxicam and the processed 
nanoparticles were done using the 8 mg dose [40] for one hour in 
0.1N HCl at pH 1.2. The cumulative percentage of the drug dissolved 
as a function of time from the prepared lyophilized formulae is 
illustrated in fig. 3. The general features of lornoxicam dissolution 
profiles revealed a high initial flash dissolve within the first 15 min 
from F1 (69.108%) and F3 (65.794%). The highest amount of drug 
dissolved after one hour was from F3 (74.484%), F5 (75.375%), F6 
(75.735%), which show insignificant differences between them 
(*P˃0.05), while F11 showed the lowest amount of drug dissolved 
(43.762%). It was clearly observed that the percentage of drug 
dissolved from raw lornoxicam was very slow (12.7%) after one 
hour. However, it was apparent that lornoxicam dissolution 
significantly (*p˂0.05) improved when the anti-solvent precipitation 
method used and nanoparticles produced, from 3.4 to 5.96 folds. 
According to Noyes-Whitney equation, the drug release rate is 
linearly proportional to the surface area exposed to the medium 
[41]. The accelerated dissolving rate of lornoxicam nanoparticles 
could be mainly ascribed to their greater surface area in comparison 
with the raw drug. The results showed that the use of stabilizers 
(Inutec SP1, or Pluronic F127, or Sucrose ester S1670) in 
concentrations near or lower than their critical micelle 
concentrations, was effective in inhibiting crystal growth due to the 
presence of the hydrodynamic boundary layer surrounding the 
nanocrystals as well as adsorption of the polymer molecules on the 
growing crystal faces [42]. The mechanism of polymer adsorption on 
the crystal surface can be explained on the basis of hydrogen 
bonding between drug molecules and polymer. Two way ANOVA 
followed by Dunnett's test in terms of percentage lornoxicam 
dissolved at given time intervals (5, 20, 60 min) from nanoparticles 
formulae and raw lornoxicam using Tukey HSD and Dunnett two 
sided showed significant difference (*P˂0.05). 
 
 
Fig. 3(a): Percentage lornoxicam dissolved from F1 to F6 in 0.1 N HCl, compared with raw lornoxicam, (mean±SD, n=3) 
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Fig. 3(b): Percentage lornoxicam dissolved from F7 to F12 in 0.1 N HCl, compared with raw lornoxicam, (mean±SD, n=3) 
 
PS analysis 
The particle size distribution of lornoxicam nanoparticles using zeta-
sizer was determined. The mean particle size and polydispersity 
index of the prepared nanoparticles were calculated from the 
autocorrelation function of the intensity of the light scattered from 
the particles. It could be seen that the mean particle size of the 
nanoparticles obtained via the anti-solvent precipitation method 
ranged from 333.45 nm to 741.825 nm which were shown in table 3. 
Particle size formation includes several steps, namely particle 
nucleation, molecular growth and agglomeration or aggregation, and 
their rate determines the final particle size and its distribution. The 
driving force for this process is the supersaturation, which determines 
not only the nucleation rate, but also the diffusion–controlled growth 
rate [43]. The lornoxicam nanoparticles were significantly 
smaller and more uniform than the raw lornoxicam, which 
indicates better solubility [44]. The increase in mean particle size 
and the polydispersity index (PDI ˃ 0.5) in some formulae could have 
been caused by the aggregation of particles during the freeze-drying. It 
can thus be concluded that the stabilizers used are effective in 
arresting the particle growth, but may not be very effective to prevent 
aggregation. Statistical analysis showed significant difference between 
formulae by one way ANOVA followed by Dunnett’s test, and the 
smallest size was F3. Therefore, the latter was considered in 
conjunction with dissolution study to reach a definite conclusion of 
enhancement of dissolution due to reduction of particle size. 
 
Table 3: Particle size measurements for different formulae 
PDI  Size (nm)  Formula 
0.778±0.053 365.825±1.375 F1 
0.558±0.028 566.525±10.124 F 2 
0.78±0.018 338.725±13.025 F 3 
0.607±0.045 461.925±14.875 F 4 
0.718±0.025 333.45±14.45 F 5 
0.425±0.035 647.475±18.825 F 6 
0.825±0.071 349.825±22.425 F 7 
0.506±0.021 502.725±20.275 F 8 
0.889±0.000 362.925±6.075 F 9 
0.347±0.031 687.062±14.388 F 10 
0.813±0.033 655.000±24 F 11 
0.412±0.033 741.825±15.275 F 12 
 *All values are (mean±SD, n=3), PDI (Polydispersity index) 
 
 
Fig. 4: Representative SEM for (a) Raw drug, (b) F3 
 
SEM 
Morphology of raw lornoxicam and the selected nanoparticles 
formula (F3) were shown in fig. 4. It can be observed that raw drug 
particles exhibited irregular shape and a broad size distribution. F3 
with the stabilizers used showed spherical or twisted cuboid shape 
in whole. Under high magnification, it could be clearly evident that 
these agglomerates or particle assemblies were composed of a large 
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number of individual nanoparticles with a size of approximately 300 
nm. 
XRD 
X-ray diffraction analysis was performed to investigate the effect of 
the anti-solvent precipitation method on the crystallinity of 
lornoxicam in the nanoparticles formulae, where the selected 
nanoparticle formulation and the raw lornoxicam powder were 
compared in fig. 5. The diffraction pattern of lornoxicam revealed 
several sharp, high-intensity peaks observed at (2θ) angles of 8.78 °, 
13.47 °, 14.31 °, 15.10 °, 18.91 °, 20.51 °, 21.53 °, 22.97 °, 24.70 °, 
25.40 °, 28.08 °, 30.49 ° and 45.84 °, indicating the crystalline nature 
of the drug, while the diffractograms of the selected nanoparticle 
formulae showed a disappearance of some diffraction peaks and 
reduction in intensity of the remaining peaks, indicating that the 
processed particles were in amorphous form. The amorphous state 
of the lornoxicam nanoparticles would also help accelerate the drug 
dissolving rate as well [41]. These promising results encourage for 
further studies on optimum formula into tablet form and in vivo 
study for enhancement of oral bioavailability of lornoxicam. 
 
 
Fig. 5: XRD patterns of Lornoxicam (D) and F3 
 
Preparation of film coated tablets by phase transition of sugar 
alcohols 
The optimum formula (F3) was prepared using the phase transition 
method by direct compression. The phase transition method was 
chosen as it is new, simple method of preparing rapid disintegrating 
tablets without any special apparatus, focused on the compactability 
of saccharides using a combination of low and high compactability 
saccharides [45]. Although, this novel preparation method reported 
by Mizumoto et al., focused on the melting point of saccharides and 
sugar alcohols in order to produce rapid disintegrating tablets of 
sufficient hardness and low disintegration time, we use these 
benefits for preparation of oral tablets in an acidic medium and the 
results were satisfied. The objectives of this study are to produce 
oral film coated tablets, which has a sufficient hardness for handling, 
as before processing the tablets were fragile, low disintegration time 
and can be manufactured by commonly used production methods 
and equipment. The composition of tablet formulae manufactured 
by the phase transition method was shown in table 4. 
 
Table 4: Composition of tablet formulae (T1, T2, T3, and T4) 
Components T1 T2 T3 T4 
Powder 59.455 49.085 60.897 53.774 
Lubricant (Pruv) 1.17 1.17 1.17 1.17 
Xylitol 4.468 4.987 4.396 4.753 
Mannitol 84.907 94.758 - - 
Lactose - - 83.537 90.303 
HPMC (E-5) 2% - 2% - 
LycoatRS720 - 2% - 2% 
Total weight 150 150 150 150 
 *All the tablet formulae components are in (mg) 
 
Characterization of tablets 
All formulations resulted in successfully elegant tablets that 
withstood manual handling. As shown in table 5, the tablets were 
located within the acceptable weight variation range. According to 
compendial standards, the tablets comply with the friability test as 
the weight loss during the friability test was less than 1%, indicating 
that the tablets were non-fragile and could be handled easily. The 
mean hardness value ranged from 3.88 to 6.79 Kg. It was apparent 
that the tablet hardness was affected by the heating process and low 
meting point sugar alcohol content. All the tablets containing about 
5% xylitol showed hardness above 2 kilo pond (kp). It is generally 
recognized that sufficient hardness would be 2 kp or higher [46, 47]. 
Xylitol in tablets would melt at 93 °C, since the melting point of 
xylitol is 93-95 °C [48]. Accordingly, the melting of xylitol caused by 
heating probably influences the hardness of tablets. It is well known 
that the tablet hardness decreases with increasing the pore size in 
case of common compressed tablets [49, 50]. However, the tablet 
hardness increased with the pore size after heating, this probably 
due to diffusion of melted xylitol in tablets and then solidified again 
when left at room temperature after heating so the hardness 
increased due to greater bonding surface area between the powder 
particles [51, 52]. It was evident that tablet formulae (T3, T4) 
containing lactose became harder after heating, compared with that 
of tablet formulae (T1, T2) containing mannitol, this is probably due 
to fine particle size of lactose powder than that of mannitol, which 
produces a greater bonding surface area with xylitol when melted. 
Added to that, (T4) was the hardest formula due to the greater 
content of lactose than that in (T3). There was significant difference 
between formulae (*P˂0.05) by one way ANOVA using post hoc 
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followed by Scheffe test, which showed homogeneity between (T3, 
T4). In vitro disintegration studies showed that (T1, T2) were of 
longer disintegration times compared with (T3, T4), added to that 
(T1, T3) were of lower disintegration time compared with (T2, T4). 
These probably attributed to the composition of (T3, T4); which 
contain amorphous form saccharide (lactose anhydrous) [53] by 
virtue of its fine particles and high solubility, the tablet formulae 
acquired hardness and brittleness and these were apparent in 
superior hardness of (T3, T4) over (T1, T2) and at the same time 
their faster disintegration. The disintegration time of T3 and 
conventional tablets were also compared and the results were 
341.5±9.62 s, and 490±10 s respectively. In T2 and T4 the film 
coating was Lycoat RS720 [54]; (hydroxyl propyl Pea starch) of 
medium viscosity and formed more cohesive films, that are less likely 
to break up or dissolve easily than HPMC E-5 (hydroxyl propyl methyl-
cellulose) which is of low viscosity. There was statistical significance 
(*P˂0.05) between formulae regarding the disintegration time by one 
way ANOVA using post hoc followed by Scheffe test. 
 
Table 5: Characterization of tablets 
 Drug Content uniformity 
(%)  











90.34±3.59 381±16.39 0 88.79±5.34 3.88±1.03 146.43±1.36 T1 
85.825±3.28 415±25.11 0.68±0.67 87.74±2.57 3.54±0.94 146.53±0.52 T2 
93.330±3.37 341. 5±9.62 0.10±0.03 90.42±1.19 5.62±1.42 146.93±1.35 T3 
81.853±4.44 364.3±10.63 0.23±0.09 85.54±2.91 6.80±1.25 148.33±1.51 T4 
*All values are (mean±SD, n=3) 
 
In vitro dissolution studies 
In film coated tablets the dissolving percentage in T1 and T3 were 
superior over the rest of the formulae which were 76.346±0.005 and 
72.107±0.002 respectively. It was also evident in fig. 6 that the 
preparing method or the excipients used have no retarding effect on 
the release of lornoxicam from tablets compared with the 
dissolution profile of optimum nanoparticle formula; such that the 
dissolving percentage from F3 was 74.484±0.005. It was also 
confirmed that the phase transition method provided the tablets 
with sufficient hardness while keeping its quick disintegration and 
dissolution rate. These results correlate well with disintegration 
time testing results, where HPMC E-5 film coating resulted in shorter 
disintegrating time than that of lycoat. These results were confirmed 
statistically by one way ANOVA using post hoc followed by Scheffe 
test, showed an insignificant difference (*P>0.05) and homogeneity 
between F3, (T1, T2, T3, T4) and between (T1, T2, T3, T4). 
 
 
Fig. 6: In vitro dissolution profiles of tablet formulae in gastric simulated fluid at pH 1.2 and 37 °C, (mean±SD, n=3) 
 
 
Fig. 7: FTIR spectra of tablet formulae compared with raw lornoxicam 
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The IR spectra of different tablet formulations and pure excipients used 
were recorded and presented in fig. 7. It was clearly apparent from tablet 
formulations that the characteristic peaks of lornoxicam were at their 
same positions with the different excipients used in tablet formulations. 
Moreover, these spectra can be simply regarded as the superimposition 
of lornoxicam spectrum and the investigated excipients spectra. This 
could indicate the absence of chemical interaction between drug and 
excipients in different tablet formulations. 
Stability studies 
The visual and physical inspection of the selected tablets (T3) 
conditioned at 25 °C/60% RH for one month [24] revealed no 
remarkable changes in the physical characteristic (texture, color, 
and porosity). Also, no remarkable change in the thickness, diameter 
and drug content of the selected tablets (T3). The hardness and 
disintegration time of tablets slightly increased with storage time. 
These data suggested that the xylitol content (5%) in the formula; used 
as low melting point sugar alcohol which was responsible during the 
heating process in phase transition method for inter-particle bonds 
between high melting point sugar alcohol (lactose) particles, required 
a long time to return to a crystalline solid. Analyzing the dissolution 
data of the stored and fresh tablets indicated that storing the tablets at 
the specified conditions (25 °C/60% RH) had no marked effect on 
drug dissolution as shown in fig. 8. In addition, sugar alcohols are 
very sensitive to humidity, so that it is important for formulation 
development to select the moisture-proof packaging to prevent 
changing of tablet properties under the humidity condition. The 
observed stability of lornoxicam in T3 tablets can be attributed to 
the lyophilization process which can enhance the product stability in 
the dry state [55, 56]. 
 
 
Fig. 8: Comparison between dissolution profiles of T3 in fresh and after 4 w of storage condition, mean of readings (n=3)±SD 
 
In vivo study and pharmacokinetic analysis 
The calibration curve of lornoxicam showed a linear response across 
the concentration range used from 1 to 1000 ng/ml. The assay 
method showed a linear relationship between lornoxicam 
concentration and its peak area ratio to the internal standard and 
the determination coefficient (R2) was found to be 0.997. As the 
assay method can be used for the quantitative determination of the 
drug in plasma [57]. The mean plasma concentration-time curves 
following the administration of Lornoxicam® 8 mg tablets and T3 
tablets were shown in fig. 9 and the mean pharmacokinetic 
parameters were reported in table 6. Results showed that the Cmax of 
T3 was 1408.92±62.194 ng/ml compared with 707.203±62.011 
ng/ml for Lornoxicam® (conventional tablets). The Cmax increased by 
1.99 folds indicating that T3 tablets, improved oral absorption of 
lornoxicam. The Tmax was the same in both T3 and conventional 
tablets which were consistent with reported values (1-2 h) [58]. It 
was observed that the AUC0-24 in T3 was higher than that of 
conventional tablets by more than 2 folds, similarly the AUC 0-∞ was 
higher by 1.99 folds. These results showed that the amount of drug 
absorbed through the optimum formula T3 was remarkably higher 
than that from conventional tablets. The relative bioavailability was 
improved by 203.794%. Finally, the elimination half-life was slightly 
shorter in T3 than conventional tablets and this indicated the 
effectiveness and the rapid action of T3 and it was consistent with 
the pharmacokinetics theory, in which an increase in absorption 
should not affect elimination. The statistical analysis comparing the 
pharmacokinetics parameters between the two treatments was the 
non-parametric test Mann-Whitney for independent samples 
showed that the mean rank of T3 in (Cmax, AUC0-24, AUC0-∞, and Kel) 
were higher than that in conventional tablets and showed significant 
difference (*P˂0.05) regarding (Cmax, AUC0-24, and AUC0-∞), while no 
significance regarding (Tmax, Kel, and t½e) and these results were 
confirmed by Wilcoxon W and Z-calculated tests. 
 
 
Fig. 9: Mean plasma lornoxicam concentrations±SD, (n=3), following administration of T3 and Lornoxicam®tablets in rabbits 
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*RB% (relative bioavailability) 




























The dissolution of lornoxicam was successfully enhanced by 
producing nanoparticles through anti-solvent precipitation using 
three different stabilizers Inutec SP1, Pluronic F127, Sucrose ester 
S1670. F3 which was formulated using Inutec SP1 displayed 
superior dissolution profile, drug content and small particle size. It 
was taken as the optimum formula and successfully manufactured 
into rapid release film coated tablets through the novel method 
(phase transition of sugar alcohols) by direct compression. T3 was 
the optimum tablet formula, which showed a superior dissolution 
profile, drug content, hardness, and disintegration time. Stability 
study on T3 showed, that the storage conditions did not affect the 
lornoxicam content, or the in vitro release, but slightly increase the 
hardness and the disintegration time. Overall, the in vivo 
pharmacokinetic study showed significantly higher Cmax, AUC0-24, and 
relative bioavailability demonstrate the potential of the formulation 
and its rapid absorption to provide effective and efficient tablets of 
lornoxicam by the oral route.  
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